iSpecimen Inc. 10-Q Summary
Business Context and Reporting Period
iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals, laboratories and other organizations providing biospecimens and related data. The company operates as one reporting segment. This unaudited Form 10-Q covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The filing was dated May 7, 2024.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $2.290 million | $2.950 million | Down 22% |
| Cost of revenue | $1.000 million | $1.147 million | Down 13% |
| Gross profit | $1.290 million | $1.803 million | Down 28% |
| Gross margin | 56.3% | 61.1% | Down 4.8 percentage points |
| Operating expenses | $5.291 million | $5.493 million | Down 4% |
| Loss from operations | $(3.001) million | $(2.542) million | Loss increased 18% |
| Net loss | $(2.902) million | $(2.432) million | Loss increased 19% |
| Basic and diluted loss per share | $(0.32) | $(0.27) | Worsened |
| Net cash used in operating activities | $(2.072) million | $(2.826) million | Improved by $0.753 million |
Revenue from specimens was $2.136 million, while shipping and other revenue was $154,000. Specimen volume declined 39%, from 8,629 to 5,241 specimens, partly offset by a 28% increase in average selling price per specimen, from approximately $342 to $437.
Cash and cash equivalents were $2.090 million at March 31, 2024. Available-for-sale securities were $466,000, resulting in cash and short-term investments of approximately $2.556 million. Current liabilities exceeded current assets by $415,000, and total liabilities were $5.701 million. The filing does not report outstanding conventional debt; liabilities primarily consisted of accounts payable, accrued expenses, deferred revenue and operating lease obligations. The company had $156,700 of current operating lease obligations and no long-term lease obligation.
Total assets were $12.514 million, compared with $15.819 million at December 31, 2023. Stockholders’ equity declined to $6.813 million from $9.741 million, primarily reflecting the quarterly net loss. Accumulated deficit was $62.267 million.
Material Changes Versus the Prior Comparable Period
- Revenue decreased $660,000, driven primarily by lower specimen volume. Higher average selling prices partially mitigated the decline.
- Gross margin declined because the average cost per specimen increased approximately 44%, while specimen volume fell.
- Technology expense increased 9% to $912,000, primarily because software amortization increased approximately $99,000.
- Sales and marketing expense declined 31%, supply development expense declined 28%, and fulfillment expense declined 10%, reflecting workforce and operating cost reductions.
- General and administrative expense increased 16% to $2.104 million, including higher professional fees, taxes and insurance, and bad debt expense.
- The allowance for doubtful accounts increased by $197,924, reflecting liquidity problems and bankruptcies among certain boutique life sciences customers. The allowance totaled $718,821 at March 31, 2024.
- Investing activities provided $1.937 million, primarily because $2.683 million of available-for-sale securities matured, partially offset by purchases of securities and software development costs.
- Internally developed software capitalization declined to $275,000 from $1.540 million.
- The company repurchased and terminated PIPE warrants covering 1.313 million shares for approximately $52,500. Remaining warrants covered 102,500 shares at March 31, 2024.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide formal quantitative revenue or earnings guidance. Management intends to increase customers and suppliers, develop revenue enhancement initiatives, reduce expenditures and invest at a substantially lower level in technology during 2024.
Management disclosed substantial doubt about the company’s ability to continue as a going concern for one year from issuance of the financial statements. The company has recurring losses, negative working capital, limited liquidity and an accumulated deficit. Management’s mitigation plans include additional revenue initiatives, further cost reductions, deferral of projects and capital expenditures, and additional public equity or debt financing. Management stated that these plans are not considered probable and therefore do not alleviate the substantial doubt.
On March 5, 2024, the company entered into an at-the-market offering allowing sales of up to $1.5 million of common stock. During the quarter, it issued 337,970 shares for approximately $138,000 of gross proceeds but incurred approximately $205,000 of offering costs, producing a net cost of approximately $67,000.
The company continues to develop a sequencing and high-value FFPE cancer-block initiative and a potential subscription database of sequenced research content. The filing describes revenue from this initiative as modest to date and does not provide a forecasted contribution.
Continuing risks include reduced research funding and discretionary customer spending, customer credit losses, specimen availability, higher shipping and operating costs, inflation, and renewed disruption from the Russia-Ukraine conflict. Ukrainian and Russian supply sites were mostly accessible at quarter-end, but transportation from Ukraine remained challenging and further sanctions or disruptions could affect supply and margins.
The company accrued approximately $710,000 of estimated sales tax liabilities and approximately $208,000 of related interest and penalties. It had recovered approximately $412,000 from certain customers and was pursuing voluntary disclosure agreements with relevant jurisdictions. Management reported a material weakness in internal control over financial reporting related to documenting customer tax exemptions and calculating, collecting and remitting sales taxes. Remediation efforts are ongoing, but the company cannot assure when the weakness will be fully remediated.
No material litigation was reported, and the filing states that there were no material changes to previously disclosed risk factors.
Most Important Facts to Verify
- Liquidity runway: approximately $2.556 million of cash and short-term investments versus quarterly operating cash use of $2.072 million.
- Going-concern disclosure and the probability and timing of additional financing.
- Progress and economics of revenue enhancement initiatives, particularly sequenced FFPE data and related subscription opportunities.
- Revenue volume trends, average selling prices, specimen acquisition costs and gross-margin recovery.
- Collectability of receivables and the adequacy of the $718,821 allowance for doubtful accounts.
- Final sales tax exposure, including amounts payable under voluntary disclosure agreements, interest and penalties, and customer recoveries.
- Remediation of the material weakness in sales-tax-related internal controls.
- Potential dilution from the remaining ATM capacity, outstanding equity awards and remaining warrants.